A practical reference on actin binding: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-27. Anything still debated is marked as such rather than presented as settled.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
| Property | Value | Notes |
|---|---|---|
| Water content | Low in freshly lyophilised material | Rises after repeated opening of the same vial |
| Solution stability | Lower than powder stability | Frozen aliquots are preferred over repeated thawing |
| Purity assessment | Reversed-phase HPLC with UV detection | Peak-area percentage excludes salts and water |
| Salt form | Often the trifluoroacetate salt | Retained from acidic purification gradients |
| Light sensitivity | Not strongly photoreactive | Dark storage still advised for long-term keeping |
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
One study found that "launch prices" for new drugs became approximately 50% higher over the three-year period from 2022 to 2024 (inclusive), with an expert saying this practice is likely to continue until it receives a policy response.
=== Noncovalent interactions === As mentioned above, aqueous chitosan has many positively charged amine groups. This makes it readily bind to negatively charged surfaces such as mucosal membranes. Chitosan can also effectively bind to other surface via hydrophobic interaction and/or cation-π interaction (chitosan as a cation source) in aqueous solution.
== History == Based in Palm Beach Gardens, Florida, UTC Climate, Controls & Security was created by splitting up UTC Building & Industrial Systems into two segments, Otis and UTC Climate, Controls & Security. Otis provides elevator and escalator manufacturing installation, while UTC Climate, Controls & Security's brands provide building technologies, heating and cooling, fire safety and security and refrigeration products and services. Through its brands, UTC Climate, Controls & Security dates back to 1818, when Jeremiah and Charles Chubb patented the world's first detector lock. In 1881, Robert Edwards patented the first electric alarm bell. In 1902, Willis Carrier developed and later patented the first modern air conditioner. And in 1917, Walter Kidde founded the Walter Kidde Company, which produced the first integrated smoke detection and carbon dioxide extinguishing system for use on board ships.
Sources: en.wikipedia.org
The script was co-written by Paul Dehn, who had worked in the Special Operations Executive as an assassin during World War II. The film closely follows the plot of the original source text. One exception is that the name of the principal female character in the novel, Liz Gold, is changed to Nan Perry in the film, reputedly because Martin Ritt was worried about the potential confusion in the media with Burton's wife, Elizabeth Taylor. Le Carré's preferred choice was Rita Tushingham, he initially felt Bloom was "too beautiful, classy," but later changed his mind, feeling she provided a proper foil to Burton. Le Carré favoured Trevor Howard or Peter Finch for the role of Leamas, but they were rejected for not being enough of a box office draw; Burt Lancaster was also considered but was rejected for not being able to put on a convincing British accent. Richard Burton, the eventual choice of the producers, butted heads with director Martin Ritt during the course of the production. The atmosphere on set was also tense from both the presence of Burton's wife, Elizabeth Taylor, as well as the romantic history between co-stars Burton and Bloom. Burton had initially demanded Taylor play Perry, but Martin Ritt insisted on Bloom. Several of the key cast and crew were expatriate Americans who had been blacklisted, including director Martin Ritt, actor Sam Wanamaker and composer Sol Kaplan. Some of the cast and crew had previously worked on the James Bond films, including screenwriter Paul Dehn (who wrote Goldfinger) and actor Bernard Lee (the original M).
== Background == The summit was held on the French shore of Lake Geneva, close to the border with Switzerland. Because delegations were expected to arrive through Geneva Airport, the event required security coordination between France, Switzerland and the Swiss cantons of Geneva, Vaud and Valais. The summit had initially been announced for 14–16 June 2026, but was later postponed by a day to 15–17 June, to avoid a clash with the planned UFC Freedom 250 mixed martial arts event held on US president Donald Trump's birthday. French president Emmanuel Macron made the reduction of global economic imbalances a priority for France's G7 presidency, citing industrial overcapacity, underinvestment, excessive debt, deregulation and low private investment in developing countries among the threats to economic stability. The summit took place in the aftermath of reports of a memorandum of understanding between the US and Iran aimed at ending the Iran War and reopening the Strait of Hormuz. Trump signed the memorandum at the Palace of Versailles on 17 June 2026, during a dinner hosted by Macron after the summit.
== Outcomes == The outcome in a particular circumstance will be determined by the tissue in which the injury has occurred—and the injurious agent that is causing it. Here are the possible outcomes to inflammation:
Sources: en.wikipedia.org
== Entry == The Clinical School was established in 1976 while construction of the new building at its present site was underway. The clinical course was restructured in 2005 with the addition of a new final year, as the clinical course had previously been less than three years in length. Before 2017, approximately half of medical students left Cambridge after the pre-clinical course as there were not enough places on the clinical course for them all; common destinations included medical schools based in Oxford, London and Manchester. From 2017, all medical students continue to study in Cambridge for the full six years provided they pass the pre-clinical component of the course. Students enter the clinical course at Cambridge following satisfactory progression during the pre-clinical component of the combined medical course or as part of the graduate course.
=== Ron Hites Award: for an exemplary paper published in the previous two volumes of the Journal of the American Society for Mass Spectrometry (since 2009) === 2022 Elyssia Gallagher 2019 Julia Laskin 2009 Alison Ashcroft
=== Pharmacokinetics === Unlike serotonin, αMS is not metabolized by monoamine oxidase on account of the α-methyl substituent blocking the enzyme's access to the amine. Similarly to serotonin however, αMS poorly crosses the blood–brain barrier due to its free hydroxyl group and poor lipophilicity, and thus may have weak or no central effects when administered peripherally.
== See also == Anorectic Eating disorder Fasting Food aversion (disambiguation) Ghrelin Gluttony Hunger strike Hypoglycemia Polyphagia Postprandial somnolence Satiety value Specific appetite Starvation Stomach rumble Taste aversion (disambiguation) Thirst Famine Prader–Willi syndrome
Sources: en.wikipedia.org
Divide it into single-use aliquots and hold them frozen at -20 °C or below, protected from light. Repeated thawing of one container is the main avoidable source of variability.
Mass spectrometry confirms identity, because the measured mass is compared with the value expected from the sequence. Chromatography mainly reports how much of the material elutes as the target peak.
It usually describes the share of the chromatographic peak area recorded at a set wavelength. Salts, residual water, and solvent are excluded from that number, so it is not the same as mass fraction.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.